NASDAQ:GRTSGritstone Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gritstone Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.28 +0.01 (+0.16 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$6.13Now: $6.28▼$6.4850-Day Range$6.27MA: $6.81▼$7.9952-Week Range$5.42Now: $6.28▼$12.96Volume324,200 shsAverage Volume163,279 shsMarket Capitalization$234.02 millionP/E RatioN/ADividend YieldN/ABeta1.41 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGritstone Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Gritstone Oncology has a potential upside of 170.7% from its current price of $6.28.Amount of Analyst CoverageGritstone Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesGritstone Oncology has received 106 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGritstone Oncology has received 94 “underperform” votes. (Add your “underperform” vote.)Community SentimentGritstone Oncology has received 53.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Gritstone Oncology and other stocks. Vote “Outperform” if you believe GRTS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GRTS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGritstone Oncology does not currently pay a dividend.Dividend GrowthGritstone Oncology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gritstone Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 22.70% of the stock of Gritstone Oncology is held by insiders.Percentage Held by Institutions77.61% of the stock of Gritstone Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gritstone Oncology are expected to grow in the coming year, from ($2.74) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gritstone Oncology is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gritstone Oncology is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGritstone Oncology has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRTS Previous Symbol CUSIPN/A CIKN/A Webwww.gritstoneoncology.com Phone510-871-6100Debt Debt-to-Equity Ratio0.17 Current Ratio6.09 Quick Ratio6.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.36 million Price / Sales53.68 Cash FlowN/A Price / Cash FlowN/A Book Value$3.75 per share Price / Book1.67Profitability EPS (Most Recent Fiscal Year)($2.81) Net Income$-94,430,000.00 Net Margins-2,397.90% Return on Equity-69.76% Return on Assets-52.35%Miscellaneous Employees113 Outstanding Shares37,265,000Market Cap$234.02 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable NASDAQ:GRTS Rates by TradingView Receive GRTS News and Ratings via Email Sign-up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter. Gritstone Oncology (NASDAQ:GRTS) Frequently Asked Questions How has Gritstone Oncology's stock been impacted by COVID-19 (Coronavirus)? Gritstone Oncology's stock was trading at $6.67 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GRTS stock has decreased by 5.8% and is now trading at $6.28. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Gritstone Oncology? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gritstone Oncology. When is Gritstone Oncology's next earnings date? Gritstone Oncology is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Gritstone Oncology. How were Gritstone Oncology's earnings last quarter? Gritstone Oncology Inc (NASDAQ:GRTS) announced its earnings results on Thursday, May, 7th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. The firm earned $1.26 million during the quarter, compared to analysts' expectations of $1.20 million. Gritstone Oncology had a negative net margin of 2,397.90% and a negative return on equity of 69.76%. View Gritstone Oncology's earnings history. What price target have analysts set for GRTS? 3 brokerages have issued 1-year price objectives for Gritstone Oncology's shares. Their forecasts range from $17.00 to $17.00. On average, they anticipate Gritstone Oncology's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 170.7% from the stock's current price. View analysts' price targets for Gritstone Oncology. Has Gritstone Oncology been receiving favorable news coverage? News coverage about GRTS stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gritstone Oncology earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View the latest news aboutGritstone Oncology. Who are some of Gritstone Oncology's key competitors? Some companies that are related to Gritstone Oncology include Orchard Therapeutics (ORTX), Krystal Biotech (KRYS), Cellectis (CLLS), Avrobio (AVRO), Nantkwest (NK), Replimune Group (REPL), AVITA MED LTD/S (RCEL), BioCryst Pharmaceuticals (BCRX), Agenus (AGEN), Aerie Pharmaceuticals (AERI), Vericel (VCEL), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Aptose Biosciences (APTO) and Oyster Point Pharma (OYST). View all competitors. What other stocks do shareholders of Gritstone Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Amarin (AMRN), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Advanced Micro Devices (AMD) and Axsome Therapeutics (AXSM). Who are Gritstone Oncology's key executives? Gritstone Oncology's management team includes the following people: Dr. Andrew R. Allen, Co-Founder, Pres, CEO & Director (Age 52)Dr. Karin Jooss, Exec. VP of Research & Chief Scientific Officer (Age 54)Prof. Raphaël F. Rousseau M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 50)Mr. Jean-Marc Bellemin M.B.A., Exec. VP of Fin. & CFO (Age 47)Dr. Roman Yelensky, Exec. VP & CTO (Age 40) When did Gritstone Oncology IPO? (GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager. What is Gritstone Oncology's stock symbol? Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS." Who are Gritstone Oncology's major shareholders? Gritstone Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Redmile Group LLC (8.23%), Casdin Capital LLC (6.09%), BlackRock Inc. (5.88%), Victory Capital Management Inc. (0.95%), Victory Capital Management Inc. (0.94%) and Ensign Peak Advisors Inc (0.94%). Company insiders that own Gritstone Oncology stock include Nicholas Simon and Raphael Rousseau. View institutional ownership trends for Gritstone Oncology. Which major investors are selling Gritstone Oncology stock? GRTS stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Ensign Peak Advisors Inc, UBS Group AG, Victory Capital Management Inc., Victory Capital Management Inc., and First Trust Advisors LP. View insider buying and selling activity for Gritstone Oncology. Which major investors are buying Gritstone Oncology stock? GRTS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Casdin Capital LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, Geode Capital Management LLC, JPMorgan Chase & Co., Nuveen Asset Management LLC, and Alliancebernstein L.P.. View insider buying and selling activity for Gritstone Oncology. How do I buy shares of Gritstone Oncology? Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Gritstone Oncology's stock price today? One share of GRTS stock can currently be purchased for approximately $6.28. How big of a company is Gritstone Oncology? Gritstone Oncology has a market capitalization of $234.02 million and generates $4.36 million in revenue each year. The company earns $-94,430,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe. What is Gritstone Oncology's official website? The official website for Gritstone Oncology is www.gritstoneoncology.com. How can I contact Gritstone Oncology? Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at www.gritstoneoncology.com. This page was last updated on 6/3/2020 by MarketBeat.com Staff
